CC
BXRX

Centiva Capital’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Centiva Capital’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8
Closed -$44K – 934
2020
Q2 		$44K Buy
+8
New +$38.4K ﹤0.01% 618

Other funds holding BXRX

NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
CCM
Corsair Capital Management New York $673M AUM 109.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $3.39B AUM 105.5% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Centiva Capital's BXRX Position: Q3 2020 in Review

Centiva Capital sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q3 2020, closing a stake of 8 shares — an estimated $44K sold.

Centiva Capital first reported a position in BXRX in Q2 2020 and held it in 1 quarter. The position peaked at $44K in Q2 2020. 26 funds tracked by Wall St. Rank hold BXRX as of Q3 2020.

  • Centiva Capital reported no remaining Baudax Bio, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Centiva Capital sold 8 Baudax Bio, Inc. Common Stock shares in Q3 2020, an estimated $44K.
  • Centiva Capital first reported a position in Baudax Bio, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Centiva Capital's Baudax Bio, Inc. Common Stock position peaked at $44K in Q2 2020.
  • 26 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q3 2020.

Based on Centiva Capital's 13F filing for Q3 2020, filed 16 Nov 2020.